Dr. Shao-Chin Chiang is a US-trained clinician with over two decades of professional experience in clinical pharmacy and hospital leadership. He currently serves as an Assistant Professor at National Yang Ming Chiao Tung University in Taiwan, holding appointments in both the Department of Pharmacy and the Ph.D. Program in Regulatory Science and Policy. Alongside his academic roles, Dr. Chiang serves as the Founder and President of the Taiwan Hematology and Oncology Pharmacy Association, as well as the Director of the Center of Advanced Pharmacy Education at the Koo Foundation Sun Yat-Sen Cancer Center.

Dr. Shao-Chin Chiang's lab provides a collaborative, multidisciplinary space for research that directly shapes modern healthcare standards. One of the lab's primary focuses is pharmacoeconomics and cost-effectiveness modeling for cutting-edge cancer therapies, including immunotherapies and biosimilars [1-8]. A second major pillar is pharmacy education and workforce development, where Dr. Chiang has led national initiatives to establish Entrustable Professional Activities and learning milestones for postgraduate pharmacist training in Taiwan [9-11]. Dr. Chiang's other key research interests include hazardous drug handling [12-14], hospital resource management [15], pharmacoepidemiology [16], and regulatory science [17-18].  

Lab's publications (selected works): 

1. Chiang ST, Chueh CH, Wen YW, Chiang SC, Li WH, Tsai YW. Cost-Effectiveness of Lenvatinib plus Pembrolizumab as the Second-Line Treatment for Advanced Endometrial Carcinoma. Cost Effectiveness and Resource Allocation. 2026 Jan 14. doi: 10.1186/s12962-025-00711-y 
2. Chen HL, Chueh CH, Huang WM, Chan SH, Cheng HH, Chiang SC, Wu CE, Wen YW, Tsai YW. Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer. Scientific Reports. 2025 Nov 10;15(1):39298.  
3. Hsu SW, Chiang SC, Hsu JC, Ko Y. Validation of Risk Models for Predicting Febrile Neutropenia Among Breast Cancer Patients Receiving Chemotherapy: A Real-World Study. Clinical Therapeutics. 2024 Dec 5. doi:10.1016/j.clinthera.2024.11.011  
4. Tseng TH, Chiang SC, Hsu JC, Ko Y. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan. PLoS ONE. 2024 Jun 10;19(6):e0303294. 
5. Chen YY, Khor W, Cheng PL, Chiang SC. Comparing drug handling efficiencies and expenses for short-acting granulocyte-colony stimulating factor injection originators and biosimilars from the perspective of hospital resource management in formulary decision-making. General Medicine and Clinical Practice. 2024 Feb 23;7(2):1–6. doi:10.31579/2639-4162/146 (Corresponding author) 
6. Hsu SW, Chiang SC, Hsu JC, Ko Y. Validation of Risk Models for Predicting Febrile Neutropenia Among Breast Cancer Patients Receiving Chemotherapy: A Real-World Study. Clinical Therapeutics. 2024 Dec 5. doi:10.1016/j.clinthera.2024.11.011  
7. Chen HM, Chen JH, Chiang SC, Lin YC, Ko Y. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study. Medicine. 2021;100(43): e27567. 
8. Chou TC, Chiang SC, Ko Y. Health state utilities for metastatic breast cancer in Taiwan. Breast. 2020;51:57-64. (Co-first author) 
9. Chang YH, Chiang SC, Yang CW. Empowering Pharmacy Faculty Training: Integrating EPAs for Enhanced Workplace Observation and Feedback Skills. Journal of Medical Education. 2024;28(1):22-31. doi:10.6145/jme.202403_28(1).0006 
10. Chang YH, Chiang SC, Yang CW. Establishment of Entrustable Professional Activities for Two-Year Post-Graduate Pharmacists: A Consensus of Multicenter Hospitals in Taiwan. Formosa Journal of Clinical Pharmacy. 2023;31(4):287-299. doi: 10.6168/FJCP.202310_31(4).0005 
11. Chang YH, Chiang SC, Yang, CW. Establishing Core Competencies of Taiwanese Pharmacists Using the Nominal Group Technique. Journal of Medical Education 2022; 26: 69-78. 
12. Chiang SC, Shen M, Lin CC, Chang HP. Establishing a protocol for the compatibilities of closed-system transfer devices with multiple chemotherapy drugs under simulated clinical conditions. PLoS One. 2021;16(9):e0257873.  
13. Chang LL, Chiang SC, Chiang MK et al. Guideline of Safe Handling for Anti-Neoplastic Hazardous Drugs- 2020. The Journal of Oncology Nursing 2020;20 suppl:5-76.
14. Chang LL, Chiang MK, Chiang SC, Chiu SY. Guidelines for Safe Handling of Hazardous Antineoplastic Drugs and Prevention of Exposure at Home. The Journal of Oncology Nursing 2020;20 suppl:77-84. 
15. Huang PP, Poon SYK, Chang SH, Kuo CW, Chien MW, Chen CC, Chiang SC. Improving the efficiency of medication reconciliation in two Taiwanese hospitals by using the Taiwan National Health Insurance PharmaCloud medication system. International Journal of General Medicine 2023;16: 211-220. (Corresponding author) 
16. Chueh CH, Yu HJ, Wen YW, Shiu MN, Chen YY, Chiang SC, Tsai YW. Impact of Same-Day ART Initiation on Medical Care and Medication Discontinuation Among Patients with Incident HIV Infection or AIDS in Taiwan: A Population-Based Cohort Study. Journal of Infection and Public Health. 2025 Jan 21:102677. (Co-corresponding author) 
17. Al-Naqqash M, Castañeda-Hernández G, Chiang SC, Ibnshamsah F, Reinert T, Rifkin RM, Morsi WE. Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer? Future Oncology 2024 Mar;20(9):481-491. doi: 10.2217/fon-2023-0756. Epub 2023 Nov 27. 
18. Poon SYK, Hsu J C, Ko Y, Chiang SC. Assessing knowledge and attitude of healthcare professionals on biosimilars: a national survey for pharmacists and physicians in Taiwan. Healthcare (Basel). 2021;9(11): 1600. (Corresponding author)